Summary:
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled,
Parallel-group Study to Assess the Safety and Efficacy of
ASP4345 as Add-on Treatment for Cognitive Impairment
in Subjects with Schizophrenia on Stable Doses
of Antipsychotic Medication
Qualified Participants Must:
• Subject is a male or female subject between 18 to 55 years of age
Qualified Participants May Receive:
Compensation for time and travel